Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Century Therapeutics has reported Current Deferred Revenue over the past 3 years, most recently at $109.2 million for Q4 2024.

  • Quarterly Current Deferred Revenue rose 2396.89% to $109.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $109.2 million through Dec 2024, up 2396.89% year-over-year, with the annual reading at $109.2 million for FY2024, 2396.89% up from the prior year.
  • Current Deferred Revenue was $109.2 million for Q4 2024 at Century Therapeutics, up from $3.6 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $109.2 million in Q4 2024 and troughed at $3.6 million in Q3 2024.
  • The 3-year median for Current Deferred Revenue is $6.4 million (2022), against an average of $14.4 million.
  • Year-over-year, Current Deferred Revenue tumbled 48.87% in 2023 and then surged 2396.89% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $7.2 million in 2022, then crashed by 38.89% to $4.4 million in 2023, then surged by 2396.89% to $109.2 million in 2024.
  • Per Business Quant, the three most recent readings for IPSC's Current Deferred Revenue are $109.2 million (Q4 2024), $3.6 million (Q3 2024), and $4.4 million (Q2 2024).